A new small molecule that can drive an extracellular-controlled hypoxic response

An international team has found through recombinant human proteins that a new small molecule called VH298 that can drive an extracellular-controlled hypoxic response.

The new study, led by Dundee University researcher Alessio Ciulli, is a new clinical approach that is critically important in the field of ischemic injury research due to brain and heart problems, as well as chronic kidney disease or chemotherapy-induced cardiovascular damage and anemia.

The use of small molecules in recent years is one of the research hot spots in new drug development, because it allows for the selective validation of new pharmacological targets and the rapid development of new compounds. However, the identification of these molecules is indeed more difficult.

According to the researchers, VH298 can inhibit the protein-protein interaction between the ubiquitin E3 ligase VHL and the HIF-1alpha transcription factor, a process similar to the selective control pathway that results in hypoxia in vivo. This work demonstrated for the first time that VHL protein as a drug intervention target. VH298 can stimulate erythropoietin (EPO) levels and resist hypoxia-induced injury.

Researcher Carles Galdeano, a member of the Computational Biology and Drug Design Research Group, graduated from the University of Barcelona School of Pharmacy with a PhD, and his previous research focused on neurodegenerative drug intervention.

Galdeano now focuses his research efforts on small molecule identification with biomedical roles in the proteasome ubiquitin system and is currently doing postdoctoral research. Flarebio offers recombinant proteins of good quality such as recombinant PIGR at great prices.